Silexion Therapeutics Corp. reconvened its 2025 annual general meeting on July 14, 2025. The shareholders approved the election of Ilan Hadar, Dror J. Abramov, Ruth Alon, Ilan Levin, Avner Lushi, Shlomo Noy, and Amnon Peled as directors on the board. The appointment of Kesselman & Kesselman as independent public accountants for the year ending December 31, 2025, was ratified. Additionally, a proposal to allow the board to effect a reverse share split of the company's ordinary shares at a ratio of 1-for-15 was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.